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Abstract
Background—Population-based studies have estimated that ≈15% of ischemic strokes are
caused by large vessel cerebrovascular disease. We determined the types of large vessel
atherosclerosis responsible for ischemic strokes in a population-based stroke study.
Methods—Patients with first-ever or recurrent ischemic stroke in the Greater Cincinnati area
were identified during 2005 at all local hospitals. Study physicians assigned ischemic stroke
subtypes. Overall event rates and incidence rates for first-ever events were calculated and age,
race, and sex-adjusted to the 2000 US population.
Results—There were 2204 ischemic strokes, including 365 strokes of large vessel subtype
(16.6% of all ischemic strokes). Extracranial internal carotid artery stenosis was associated with
8.0% of all ischemic strokes, while extracranial internal carotid artery occlusion and intracranial
atherosclerosis were each associated with 3.5% of strokes. The annual rate of first-ever and
recurrent stroke attributed to extracranial internal carotid stenosis was 13.4 (11.4–15.4) per
100,000 persons. We conservatively estimate that ≈ 41,000 strokes may be attributed to
extracranial internal carotid artery stenosis annually in the United States.
Conclusions—Large vessel atherosclerosis is an important cause of stroke, with extracranial
internal carotid artery stenosis significantly more common than extracranial internal carotid artery
occlusion or intracranial atherosclerotic disease.
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Introduction
Large vessel atherosclerotic cerebrovascular disease is an important cause of stroke that
produces a higher risk of early recurrent ischemia than any other stroke subtype.1 Risk
factors for large vessel disease also differ from other stroke subtypes.2, 3 Importantly, for
patients with stroke or TIA attributed to severe (> 70%) extracranial internal carotid artery
(ICA) stenosis, prompt revascularization with carotid endarterectomy produces a dramatic
reduction in recurrent stroke risk.4
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Prior population-based studies have estimated that ≈15% of ischemic strokes are caused by
large vessel atherosclerosis.2, 5, 6 However, these studies have generally not distinguished
between vessel stenosis and occlusion, anterior and posterior circulations, or extracranial
and intracranial locations. We determined the types of large vessel atherosclerosis
responsible for ischemic strokes in a large, population-based stroke study. We focused
especially upon extracranial ICA stenosis because of the pronounced benefit of appropriate
treatment for this stroke mechanism.
Methods
This study was undertaken as part of the Greater Cincinnati/Northern Kentucky Stroke
Study (GCNKSS). The GCNKSS was funded by the National Institute of Neurological
Disorders and Stroke. The institutional review board for each participating hospital system
approved the GCNKSS study. Methods of the GCNKSS have been previously published.7, 8
In 2005, study nurses screened the medical records of all inpatients with primary or
secondary stroke-related ICD-9 discharge diagnoses (430–436) from all acute-care hospitals
in the study region. Patients with stroke not found by inpatient screening were ascertained
by monitoring all stroke-related visits to hospital emergency departments (with the
exception of Cincinnati Children’s Hospital) and screening of coroner’s cases. The
GCNKSS also included monitoring of university and public health clinics as well as a
sampling scheme of private outpatient physician offices and nursing homes.7 For this
analysis only patients presenting to an emergency room or hospital were included. Residents
of the five county GCNK region seek care almost exclusively at one of the metropolitan
hospitals included in the study.9 Patients living outside of the five counties of interest were
excluded by zip code of residence.
Study nurses performed chart abstraction for all potential cases. These abstracts were
reviewed in detail by study physicians. Physicians assigned a stroke category and
mechanism to each event based upon all available information, using criteria previously
reported.6, 7 Subtyping of ischemic stroke cases was performed using criteria adapted from
the Classification of Cerebrovascular Diseases III and epidemiologic studies in Rochester,
Minnesota.6, 10–13 Large vessel etiology required ≥ 50% stenosis or occlusion of the relevant
vessel. For this analysis patients with appropriate large vessel disease who also had a cardiac
source of embolism (e.g. atrial fibrillation) or a lacunar infarction were categorized as large
vessel etiology because a) some previous studies of carotid endarterectomy have included
patients with potential stroke mechanisms other than large vessel disease14, 15 and b)
clinicians often recommend endarterectomy for patients with stroke in the territory of
significant carotid atherosclerosis despite other potential stroke mechanisms. Vascular
dissections and perioperative strokes were not included as large vessel etiology. Isolated
occlusions of the carotid terminus, middle cerebral artery, anterior cerebral artery, basilar
artery, and posterior cerebral arteries were not considered large vessel because of our
inability to distinguish embolus from in situ thrombosis. Cases with stenosis of both the
distal common carotid artery and proximal internal carotid artery were classified as internal
carotid artery stenosis. Tandem lesions were categorized according to the judgment of an
investigator (M.L.F.). For this analysis patients with symptoms lasting < 24 hours but with
DWI MRI sequences positive for acute stroke were classified as stroke cases.
To estimate the total burden produced by large vessel disease, event rates including both
first-ever and recurrent ischemic strokes were calculated and age, race, and sex-adjusted to
the 2000 US population. Incidence rates were then recalculated including only patients with
first-ever ischemic stroke. For the calculation of event and incidence rates, the entire
population of the five GCNK counties was considered at risk. Denominator age-, race- and
sex-specific population estimates for each study year were obtained from published census
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data.16 We applied overall age, race-, sex-adjusted event rates to the population of the
United States in 2010 to estimate the total number of strokes attributable to extracranial
internal carotid artery stenosis and occlusion annually. Our rates and estimates were not
adjusted for patients who did not have vascular imaging or patients with stroke treated only
in the outpatient setting.
Results
There were 2096 patients with 2204 first or recurrent ischemic strokes identified. The
distribution of vascular imaging is presented in Table 1. Among these cases 79% had
cervical vascular imaging with carotid ultrasound, MR angiography, CT angiography, or
conventional cerebral angiography. Slightly less than one-half of our patients had some form
of intracranial vascular imaging. Imaging rates for cervical vessels did not differ between
black and white patients (78% vs. 75%, p=0.24), however black patients were more likely to
have intracranial vascular imaging (55% vs. 41%, p=<0.001). Male patients were more
likely to have imaging than female patients for both extracranial vessels (79% vs. 73%,
p<0.001) and intracranial vessels (48% vs. 40%, p<0.001). There were 348 patients with 365
strokes determined to be of large vessel mechanism (16.6% of all ischemic strokes). Of
these, 22 had symptoms lasting < 24 hours but positive DWI imaging on MRI. A breakdown
of large vessel cases is presented in Table 2. There were 176 strokes attributed to
extracranial ICA stenosis (8.0% of all strokes) and 78 strokes attributed to extracranial ICA
occlusion (3.5% of all strokes). Intracranial large vessel atherosclerosis accounted for 78
cases (3.5% of all strokes). There were 10 patients with tandem lesions who were
categorized with the vessel felt most likely to be causative. Among 365 strokes with large
vessel mechanism, 21.1% also had a potential cardiac source of embolus and 4.9% had a
lacunar phenotype. Incidence rates for stroke attributed to extracranial ICA disease are
presented in Table 3. Supplemental table 3a presents rates after exclusion of cases with a
potential cardiac source of embolus or lacunar phenotype. We conservatively estimate that ≈
41,000 strokes may be attributed to extracranial ICA stenosis and ≈18,000 strokes attributed
to extracranial ICA occlusion annually in the United States, based on a projected 2010
population of 308,000,000.
Discussion
Large vessel atherosclerotic disease is of great importance to clinicians caring for patients
with stroke or TIA because of its frequent occurrence, high risk of causing early recurrent
ischemia, and treatable nature. Extracranial ICA stenosis is especially notable in this regard,
as large studies have demonstrated that prompt endarterectomy markedly reduces risk of
recurrent stroke.4 Our study shows that extracranial ICA atherosclerosis is the most
important cause of large vessel stroke. There has been appropriate interest in determining
the best treatment for extracranial ICA stenosis, most notably with multiple trials comparing
carotid endarterectomy to carotid artery stenting.17–20 Although we have documented that a
substantial number of strokes are attributable to ICA stenosis, most patients with
asymptomatic carotid stenosis do not subsequently have strokes. Thus, our data do not imply
that all patients with asymptomatic carotid stenosis should undergo revascularization.
Stroke attributed to extracranial ICA occlusion occurs at approximately half the rate of
stroke due to ICA stenosis. The recently completed “Carotid Occlusion Surgery Study”
(COSS) failed to show a benefit for extracranial-intracranial bypass among patients with
carotid occlusion judged at high risk of recurrent stroke by PET imaging.21 Patients with
sypmtomatic intracranial large vessel stenosis are also known to be at high risk of
recurrence. The SAMMPRIS Trial tested intracranial stenting plus medical management vs.
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medical management alone and was closed early due to high peri-procedural risk of stroke
or death in the stenting group.22 Long term follow-up of subjects in SAMMPRIS continues.
Our study has limitations. Twenty-one percent of patients evaluated in an emergency room
or hospital for ischemic stroke did not have documented cervical vascular imaging. In some
cases imaging may have been performed in the outpatient setting (which we could not
ascertain); in other cases it may have been omitted due to the presence of another stroke
mechanism (e.g. atrial fibrillation), a devastating stroke where no intervention was planned,
patient preference, or physician oversight. Our imaging rate is comparable to or higher than
other population-based studies2, 3, 23. Extracranial imaging was considerably more common
than intracranial imaging. Although this likely occurred for several reasons, the most
important was practical: carotid revascularization is of proven benefit for high grade
extracranial ICA stenosis, while there are no proven therapies for intracranial stenosis
beyond standard medical management. The result is an underestimation of intracranial
atherosclerosis as a stroke mechanism.
We found no difference in imaging rates of cervical vessels by race. Black patients were
more likely to have intracranial imaging than whites. This may have occurred because of
higher reported rates of intracranial atherosclerosis among blacks24 or a higher percentage of
black patients being hospitalized at tertiary or academic hospitals. Women were less likely
than men to have imaging of cervical or intracranial vessels. While physician bias is one
potential explanation, other factors such as alternative stroke mechanisms, patient age and
premorbid status, and stroke severity may be relevant. Further analysis of this question is
beyond the scope of this report.
Approximately 10–20% of ischemic stroke patients in our community are evaluated on an
outpatient basis.8 They would not be captured in our data, but we have no reason to believe
they have a significantly different balance of stroke mechanisms. We did not include TIAs
(without diffusion restriction on MRI) in this analysis because estimating the true burden of
TIA in a large community is very difficult. Patients with TIA caused by large vessel stenosis
arguably have the most to gain from prompt evaluation and intervention to prevent a
potentially devastating stroke.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 3
Event rates for stroke attributed to extracranial internal carotid artery stenosis and occlusion*
Stenosis Occlusion
First-ever events First-ever and
recurrent events
First-ever events First-ever and
recurrent events
All
n=140 n=176 n=48 n=78
10.7 (8.9, 12.5) 13.4 (11.4, 15.4) 3.7 (2.6,4.8) 6.0 (4.6, 7.3)
Male
n=70 n=87 n=26 n=45
13.3 (10.1, 16.4) 16.5 (13.0, 20.0) 4.7 (2.8, 6.5)^ 7.8 (5.5, 10.1)
Female
n=70 n=89 n=22 n=33
8.8 (6.7, 10.9) 11.3 (8.9, 13.7) 2.9 (1.7, 4.1)^ 4.4 (2.9, 5.9)
White
n=123 n=153 n=43 n=67
10.8 (8.9, 12.7) 13.4 (11.3, 15.6) 3.8 (2.7, 5.0) 6.0 (4.6, 7.4)
Black
n=17 n=23 n=5 n=11
10.2 (5.3, 15.0)^ 13.6 (8.0, 19.2)^ 2.8 (0.3, 5.3)^ 6.1 (2.4, 9.7)^
*
Rate per 100,000 persons per year, adjusted to the 2000 United States population.
^Small cell sizes (< 30) may produce unstable estimates.
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